NCT07235982 Shoulder Anterior Capsular Block and Intraarticular Steroid Injection Versus Intraarticular Steroid Injection for Enhancing Pain Relief in Adhesive Capsulitis
| NCT ID | NCT07235982 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zagazig University |
| Condition | Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-10-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Improving pain in the patients with adhesive capsulitis by comparing the effect of combined shoulder anterior capsular block and intraarticular steroid injection versus intraarticular steroid injection.
Eligibility Criteria
Inclusion Criteria: * Patients acceptance * Age: 41-65 years old * Sex: both sex (males or females). * Physical status: American Society of Anesthesiologist (ASA) І, II. * Patients attend orthopedic or pain clinic with complaint of shoulder pain and stiffness. These patients received conservative management of pain with no relief of symptoms for at least 2 weeks. Exclusion Criteria: * Shoulder pain due to secondary causes, e.g. acute trauma, fractures, bony deformity, glenohumeral joint pathology, acromioclavicular joint pathology and rotator cuff disorder. * Patient with any contraindications of regional blocks (as coagulopathy or local infection at injection site) * Patients with known history of allergy to the study drugs (bupivacaine and methylprednisolone). * Advanced hepatic, renal, cardiovascular, neurologic and respiratory diseases, uncontrolled diabetes mellitus and thyroid. * History of neuropathy in the involved limb or previous revision surgery.
Contact & Investigator
Dina Salem, MD
PRINCIPAL INVESTIGATOR
FACULTY OF MEDICINE, ZAGAZIG UNIVERSITY
Frequently Asked Questions
Who can join the NCT07235982 clinical trial?
This trial is open to participants of all sexes, aged 41 Years or older, up to 65 Years, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07235982 currently recruiting?
Yes, NCT07235982 is actively recruiting participants. Contact the research team at dinamaghraby@yahoo.com for enrollment information.
Where is the NCT07235982 trial being conducted?
This trial is being conducted at Zagazig, Egypt.
Who is sponsoring the NCT07235982 clinical trial?
NCT07235982 is sponsored by Zagazig University. The principal investigator is Dina Salem, MD at FACULTY OF MEDICINE, ZAGAZIG UNIVERSITY. The trial plans to enroll 50 participants.